CAR-T cell therapy: a potential new strategy against prostate cancer

Schepisi, Giuseppe; Cursano, Maria Concetta; Casadei, Chiara; Menna, Cecilia; Altavilla, Amelia; Lolli, Cristian; Cerchione, Claudio; Paganelli, Giovanni; Santini, Daniele; Tonini, Giuseppe; Martinelli, Giovanni; De Giorgi, Ugo

doi:10.1186/s40425-019-0741-7

Table 2 CAR-T cell therapy studies on prostate cancer

From: CAR-T cell therapy: a potential new strategy against prostate cancer

Publication	Publication year	Country	Institution	Setting	Cell source and type	Generation	Costimulatory domain
Gade et al [72]	2005	USA	Memorial Sloan-Kettering Cancer Center	Preclinical - mice model	Anti PSMA CAR-T cells	First generation	–
Maher et al [73]	2002	USA	Memorial Sloan-Kettering Cancer Center	Preclinical	Anti PSMA CAR-T cells	Second generation	CD28
Zuccolotto et al [74]	2014	Italy	University of Padua	Preclinical - mice model	Anti PSMA CAR-T cells	Second generation	CD28
Ma et al [75]	2014	USA	Roger Williams Med Center	Preclinical - mice model	Anti PSMA CAR-T cells	Second generation	CD28
Slovin et al [76]	2017	USA	Memorial Sloan-Kettering Cancer Center	Phase I NCT01140373	Autologous T Anti PSMA CAR-T cells	Second generation	CD28
Kloss et al [77]	2019	USA	University of Pennsylvania	Preclinical - mice model	Anti PSMA-TGFβ insensitive CAR-T cell	Second generation	4-1BB
Zhang et al [78]	2018	UK	Oxford University	Preclinical - mice model	Anti PSMA-TGFβ insensitive CAR-T cell	Second generation	4-1BB
Hassani et al [79]	2019	Iran	Tehran Univ Med Science	Preclinical - mice model	VHH-CAR-T cell anti PSMA	Second generation	CD28
Priceman et al [80]	2017	USA	City of Hope, Duarte	Preclinical - mice model	Anti PSCA CAR-T cell	Second generation	4-1BB
Hillerdal et al [81]	2014	Sweden	Uppsala University	Preclinical - mice model	Anti PSCA CAR-T cell	Third generation	CD28, OX-40 CD3ζ
Kloss et al [82]	2012	USA	Memorial Sloan-Kettering Cancer Center	Preclinical - mice model	Anti PSCA/Anti PSMA CAR-T cell	Third generation	4-1BB, CD28
Feldman et al [83]	2017	Germany	Institute of radiopharmaceutical Cancer Research, Dresden	Preclinical - mice model	Anti PSCA/Anti PSMA CAR-T cell	Second generation	CD28
Deng et al [84]	2015	China	Cancer Hospital & Institute	Preclinical - mice model	Anti EpCAM CAR-T cell	Second generation	CD28
NCT03873805	2019	USA	City of Hope, Duarte	Phase I	Anti PSCA CAR-T cell	Second generation	4-1BB

Abbreviations: CAR chimeric antigen receptor, PSMA prostate-specific membrane antigen, TGFβ transforming growth factor β, PSCA prostate stem cell antigen, EpCAM epithelial cell adhesion molecules, VHH camelid nanobody

Back to article page